Question 1

What are the potential side effects of Brentuximab vedotin and lenalidomide?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma clinical trial (NCT03302728). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma clinical trial (NCT03302728). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like for me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma clinical trial (NCT03302728). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma clinical trial (NCT03302728). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma clinical trial (NCT03302728). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures I will need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma clinical trial (NCT03302728). Contact the study team or your healthcare provider for specific answers.

What this study is about